Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Harley Street

3 May 2016 09:01

RNS Number : 0126X
Advanced Oncotherapy PLC
03 May 2016
 

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Update on Harley Street

 

Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, notes that a number of shareholders have raised concerns that a planning application submitted by Howard de Walden Estates Limited for 141-143 Harley Street was withdrawn in January 2016 and that this will have an impact on the Company's progress.

 

Howard de Walden Estates and Advanced Oncotherapy have confirmed that the withdrawn planning application was for 'use swap' purposes only and did not involve any works to the building which are part of creating the Proton Beam Therapy Facility.

 

The application was withdrawn as the area of the facility had grown in size, as referenced in the update provided on 28 July 2015, and since the original 50 year lease agreement was signed with Howard de Walden Estates in January 2015, the available space for the centre has increased by approximately 50% allowing for an additional treatment room and additional imaging facilities.

 

Howard de Walden Estates are satisfied that progress for the site remains on track. The total cost of the redevelopment is being borne by Howard de Walden Estates.

 

 

 

Advanced Oncotherapy Plc

www.avoplc.com

Michael Sinclair, Chief Executive Office

Tel: +44 20 3617 8728

Nicolas Serandour, Chief Operating and Financial Officer

 

 

 

Stockdale Securities (Nomad & Joint Broker)

 

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

 

 

Beaufort Securities (Joint Broker)

 

Jon Belliss / Elliot Hance

Tel: +44 20 7382 8300

 

 

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

    

 

 

 

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy's team "ADAM" based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

 

The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers. In October 2015 the Company signed a joint venture agreement with CircleHealth to operate the Company's proton beam cancer therapy centre in Harley Street.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSSUSWDFMSEII
Date   Source Headline
3rd Mar 20225:05 pmRNSDirector/PDMR Notification
2nd Mar 20224:10 pmRNSDirector/PDMR Notification
1st Mar 20227:00 amRNSOperational update
28th Feb 20225:00 pmRNSTotal Voting Rights
17th Feb 20224:25 pmRNSExercise of Warrants and Issue of Equity
31st Jan 20225:00 pmRNSTotal Voting Rights
13th Jan 20223:17 pmRNSExercise of Warrants and Issue of Equity
31st Dec 20211:00 pmRNSTotal Voting Rights
13th Dec 20217:00 amRNSTechnical update on delivery of first LIGHT system
10th Dec 20217:00 amRNSHolding(s) in Company
3rd Dec 20215:09 pmRNSHolding(s) in Company
2nd Dec 20211:29 pmRNSIssue of warrants and equity and Loan Extension
30th Nov 20215:00 pmRNSTotal Voting Rights
15th Nov 20218:30 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): On the home straight
10th Nov 202111:23 amRNSHolding(s) in Company
8th Nov 20212:28 pmRNSExercise of Warrants and Issue of Equity
4th Nov 20211:44 pmRNSHolding(s) in Company
27th Oct 20217:00 amRNSPresentation highlights LIGHT system superiority
30th Sep 20215:00 pmRNSTotal Voting Rights
30th Sep 20217:00 amRNSInterim Results
23rd Sep 202111:27 amRNSExercise of Warrants and Issue of Equity
20th Sep 20217:00 amRNSUpdate re admission of Subscription Shares
3rd Sep 20217:00 amRNSUpdate on admission of Subscription Shares
31st Aug 20216:14 pmRNSResult of GM, TVR and clarification re warrants
16th Aug 20214:48 pmRNSExercise of Warrants and Issue of Equity
12th Aug 20211:50 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO) Funded to completion
11th Aug 20217:00 amRNSProposed subscription and issuance of shares
2nd Aug 20213:37 pmRNSResult of AGM
30th Jul 20214:58 pmRNSResult of AGM
13th Jul 20212:19 pmRNSHoldings in company
30th Jun 20217:00 amRNSFinal Results for the year ended 31 December 2020
3rd Jun 20217:00 amRNSSaba Partners sign LOI for LIGHT system
28th May 20215:00 pmRNSTotal Voting Rights
26th May 202110:37 amRNSExercise of Warrants and Issue of Equity
28th Apr 20215:38 pmRNSExercise of Warrants and Issue of Equity
31st Mar 20215:00 pmRNSTotal Voting Rights
12th Mar 20217:00 amRNSStudy shows the potential superiority of LIGHT
11th Mar 20217:00 amRNSExercise of Warrants and Issue of Equity
26th Feb 20215:00 pmRNSTotal Voting Rights
17th Feb 202110:39 amRNSExercise of Warrants and Issue of Equity
22nd Jan 20217:00 amRNSEquity fundraise of c.£5.9m
13th Jan 20217:00 amRNSExercise of Warrants and Issue of Equity
11th Jan 20217:00 amRNSTechnical update
6th Jan 202111:05 amRNSSecond Price Monitoring Extn
6th Jan 202111:00 amRNSPrice Monitoring Extension
6th Jan 20217:00 amRNSFinancing partnership agreement with DiaMedCare AG
15th Dec 20207:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Leveraging the modularity of LIGHT
23rd Nov 20202:42 pmRNSHolding(s) in Company
17th Nov 20202:02 pmRNSHolding(s) in Company
10th Nov 20207:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.